Fig. 1 · Structure

Documents & Downloads

Candesartan cilexetil

Cat. No. A10176 CAS 145040-37-5
Candesartan is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

After oral administration, TCV-116 (candesartan cilexetil) reduced angiotensin-II radioligand binding in AT1-rich rat tissues more strongly than in the AT2-rich adrenal medulla. These findings support receptor engagement after prodrug administration; they do not measure a direct binding constant for intact cilexetil. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Ang II receptor 0.26 nM

Cellular Effect

Cell Line Activity Value Description Reference
16HBE14o- IC50 > 100 μM Cytotoxicity against human 16HBE cells after 48 hrs by CCK-8 assay [PMID: 31732254]
A-431 IC50 2.6 μM Inhibition of IDO in human A431 cells assessed as kynurenine production after 24 hrs 10.1039/C2MD00278G
A549 IC50 63.93 μM Antiproliferative activity against human A549 cells measured after 48 hrs by CCK8 assay [PMID: 31732254]
A549 IC50 65.92 μM Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK-8 assay [PMID: 33129593]
BEAS-2B IC50 79.76 μM Cytotoxicity against human BEAS-2B cells incubated for 48 hrs by CCK-8 assay [PMID: 33129593]
BEAS-2B IC50 89.94 μM Cytotoxicity against human BEAS2B cells after 48 hrs by CCK-8 assay [PMID: 31732254]
EKVX IC50 > 100 μM Antiproliferative activity against human EKVX cells measured after 48 hrs by CCK8 assay [PMID: 31732254]
HepG2 IC50 > 100 μM Antiproliferative activity against human HepG2 cells measured after 48 hrs by CCK8 assay [PMID: 31732254]
Huh-7 IC50 > 100 μM Antiproliferative activity against human HuH7 cells measured after 48 hrs by CCK8 assay [PMID: 31732254]
MCF7 IC50 > 100 μM Antiproliferative activity against human MCF7 cells measured after 48 hrs by CCK8 assay [PMID: 31732254]
MGC-803 IC50 57.14 μM Antiproliferative activity against human MGC803 cells measured after 48 hrs by CCK8 assay [PMID: 31732254]
MKN-45 IC50 68.87 μM Antiproliferative activity against human MKN45 cells measured after 48 hrs by CCK8 assay [PMID: 31732254]
NCI-H1299 IC50 45.02 μM Antiproliferative activity against human H1299 cells incubated for 48 hrs by CCK-8 assay [PMID: 33129593]
NCI-H1299 IC50 45.11 μM Antiproliferative activity against human H1299 cells measured after 48 hrs by CCK8 assay [PMID: 31732254]
PLC IC50 60.21 μM Antiproliferative activity against human PLC cells measured after 48 hrs by CCK8 assay [PMID: 31732254]
T47D IC50 64.35 μM Antiproliferative activity against human T47D cells measured after 48 hrs by CCK8 assay [PMID: 31732254]

16 records · Scroll to view more

Candesartan cilexetil Research Summary

This section summarizes 1 in vivo study of Candesartan cilexetil from 1 published reference.

Candesartan cilexetil In Vivo Studies

A single oral 1 mg/kg TCV-116 dose reduced aortic receptor binding at 4 h, and binding remained below control at 24 h. Responses varied by tissue, with weaker effects in adrenal medulla. This tissue-binding experiment does not establish antihypertensive efficacy or functional central nervous system activity. [1]

Tissue angiotensin-II receptor binding after oral TCV-116

Animal study · Adult male Sprague-Dawley rats, 250–290 g; tissue sections assessed by quantitative autoradiography after oral treatment. [1]

One oral dose reduced subsequent radioligand binding in AT1-rich tissues, with partial recovery at 24 h. Binding in AT2-rich adrenal medulla was less affected. This is an ex vivo tissue-binding endpoint after animal exposure, not a direct potency estimate for intact cilexetil or proof of functional central antagonism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Thoracic aortic angiotensin-II receptor binding densityRadioligand binding (dpm/mm²; mean ± SD) Control: 8.7 ± 2.3; 4 h: 5.0 ± 1.0; 24 h: 5.2 ± 0.6; both treated time points p<0.01 vs control.[1]
Adrenal-medullary angiotensin-II receptor binding relative to controlPercentage of control binding 80.7% at 4 h; 88.3% at 24 h (author-reported percentages).[1]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Once
Treatment course
Tissue collection at 4 and 24 h
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Single oral TCV-116, 1 mg/kg
1 mg/kg
Predose control tissue sections processed in parallel with treated sections; nonspecific binding defined with excess unlabeled [Sar1,Ile8]Ang II.Aortic binding remained reduced at 24 h; the AT2-rich adrenal medulla showed weaker reduction.[1]
Single oral TCV-116, 1 mg/kg
Model: Adult male Sprague-Dawley rats; separate terminal tissue collections.
Reported limits: Vehicle not specified in inspected Methods; Table 1 does not restate its sample count. Methods state four rats at each time point and eight sections per tissue per rat; sections are not independent animals.
Methods and source locations

Compound reported in the paper: Candesartan cilexetil; Compound label in the paper: TCV-116

Applies to oral exposure to the reported prodrug in rats. Does not establish Adooq lot performance or assign the metabolite’s direct receptor affinity to the prodrug.

Methods p. 132; Figures 3–4 pp. 134–135; Table 1 p. 136; Results pp. 136–137; Discussion p. 138

Thoracic aortic angiotensin-II receptor binding density: Quantitative autoradiography using 125I-[Sar1,Ile8]Ang II; nonspecific binding assessed with excess unlabeled ligand. — Table 1, p. 136 (aorta row); Methods p. 132; Figure 3J–L, p. 134

Adrenal-medullary angiotensin-II receptor binding relative to control: Same autoradiographic time-course series; adrenal medulla is described as AT2-predominant. — Results p. 137, adrenal paragraph; Table 1, p. 136 (medulla row); Figure 3G–I, p. 134

Single oral TCV-116, 1 mg/kg · Methods p. 132, Animals and tissue preparation / In vitro quantitative autoradiography; Table 1 p. 136; Results p. 137

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 145040-37-5
Formula C33H34N6O6
Molecular Weight 610.7
Synonyms Amias; Blopress; Ratacand; TCV 116; TCY 116; Atacand
SMILES
CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC6

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 113 mg/mL (185.04 mM)
Water Insoluble
Ethanol 4 mg/mL (6.55 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Candesartan cilexetil Research References

  1. [1] Keifu Song, Hironori Kanehara, Shinji Takai, et al. Inhibition of the Angiotensin II Type 1 Receptor by TCV-116: Quantitation by In Vitro Autoradiography Japanese Journal of Pharmacology (1999). PMID: 10202848 DOI: 10.1254/jjp.79.131 Source material

Added to your cart

View Cart Checkout
Loading...